The ctDNA-based postoperative molecular residual disease status in different subtypes of early-stage breast cancer.

This real-world study confirmed that patient samples of primary tumor tissue with different MRD status and molecular subtypes had differential genetic features, which may be used to predict patients at high risk for recurrence.